Compare Goldman Sachs Group Inc (GS) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Medtronic PLC — how do they compare? Goldman Sachs Group Inc trades at $1,115.18 (market cap $339.87B), while Medtronic PLC trades at $83.8 (market cap $103.01B). The key difference: Goldman Sachs Group Inc is far larger — about 3.3× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| GS | MDT | |
|---|---|---|
Market Cap | $339.87B | $103.01B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $105.35 |
52-Week Low | $700.41 | $73.75 |
Dividend Yield | 1.56% | 3.58% |
Enterprise Value | — | $121.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
Medtronic (MDT) trades at $79.30, down 5.11% over 24 hours, with technical indicators showing bearish momentum. Fundamentally, the company reported strong earnings beats for three consecutive quarters and maintains solid profitability with a 13.2% net income margin. Recent news highlights the completion of the Scientia Vascular acquisition and bullish analyst coverage citing undervaluation and growth in cardiovascular and neuroscience segments.
The stock presents a compelling opportunity with a consensus price target of $97.50 representing 23% upside, supported by 58% analyst buy ratings. Key risks include increasing debt-to-asset ratios (31.11% in 2025) and margin pressures from tariffs and foreign exchange. The dividend aristocrat offers a near-decade high yield with consistent dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
